Gene-Engineered immune cells take on Hard-to-Treat myeloma
NCT ID NCT03602612
First seen Mar 03, 2026 · Last updated Jun 19, 2026 · Updated 17 times
Summary
This early-phase trial tested a new gene therapy for multiple myeloma, a blood cancer that often resists standard treatments. Researchers took participants' own immune cells (T cells), modified them in the lab to recognize a protein called BCMA on myeloma cells, and infused them back after a short course of chemotherapy. The study enrolled 35 adults whose myeloma had not been controlled by prior therapies, primarily to check the safety and find the best dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOMA MULTIPLE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Anti-BCMA CAR T cells (a type of gene therapy using the patient's own immune cells) plus chemotherapy (cyclophosphamide and fludarabine)
What this could lead to
If it works, this could point toward a new treatment option for multiple myeloma that has stopped responding to standard therapies.
What could go wrong
This is a very early phase 1 trial with only 35 people, focused on safety. The treatment may cause severe side effects, and it is not yet known if it effectively controls the cancer long-term.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.